| A | B | C | D | E | F | G | H | |
|---|---|---|---|---|---|---|---|---|
1 | ESOPHAGEAL CANCER - CLINICAL TRIALS | |||||||
2 | Source: | |||||||
3 | http://www.cancer.gov - Clinical Trials | |||||||
4 | Cancer Type: Esophageal Cancer | |||||||
5 | Stage/Subtype: Stage IV and Recurrent | |||||||
6 | ||||||||
7 | ICAN advises every patient and other interested person, after reviewing this clinical trials spreadsheet, to check out clinical trials directly at www.cancer.gov in case there are updates since the date of this posting. ICAN does not purport to provide medical advice or to indicate which trial is suitable for a certain patient. Please consult your medical oncology team and the principal investigator in charge of the trial in which you are interested for information most relevant to your specific medical situation and decision-making process. | |||||||
8 | Contact Information | |||||||
9 | No. | Link | Official Title | Purpose | Citation | Organization/Sponsor | Collaborator | Status |
10 | ||||||||
11 | 1 | http://clinicaltrials.gov/ct/show/NCT00274885 | Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin | This phase IV trial is studying the relationship between platinum levels in the blood and neurotoxicity in patients who are receiving oxaliplatin for gastrointestinal cancer. | http://clinicaltrials.gov/ct/show/NCT00274885 - Retrieved August 2011 | Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) | The recruitment status of this study is unknown because the information has not been verified recently. | |
12 | 2 | http://clinicaltrials.gov/show/NCT00754468 | A study of Cryospray Ablation(TM) Using Surgical Resection Specimens to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus (CSA Depth 3) | The purpose of this study is to evaluate the treatment effect, depth of injury, and side effects using technology involving the spray of liquid nitrogen through a catheter (CryoSpray AblationTM, "CSA" or "cryospray therapy") onto healthy tissue via esophagogastroduodenoscopy (EGD) using surgical resection specimens from subjects undergoing esophagectomy. | http://clinicaltrials.gov/show/NCT00754468 - Retrieved August 2011 | CSA Medical, Inc. | Currently recruiting | |
13 | 3 | http://clinicaltrials.gov/show/NCT01038154 | Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer | Refer to clinical trials website. | http://clinicaltrials.gov/show/NCT01038154 - Retrieved August 2011 | Hospital Donostia | Currently recruiting | |
14 | 4 | http://clinicaltrials.gov/show/NCT01260194 | An Open-label, Multicentre Phase IV Study of Trastuzumab in Combination With the Standard Therapy (as Per Routine Clinical Practice) as First-line Therapy in Patients With HER2 Positive Metastatic Gastric Cancer | This open-label, multi-center study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with standard chemotherapy as first-line treatment in patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction. Patients will receive standard chemotherapy for a maximum of 6 cycles, and 8 mg/kg Herceptin as loading dose on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression. | http://clinicaltrials.gov/show/NCT01260194 - Retrieved August 2011 | Hoffmann-La Roche | This study is not yet open for participant recruitment. | |
15 | 5 | http://clinicaltrials.gov/show/NCT00332280 | A Prospective, Randomised, Multicenter Phase II/III Clinical Trial to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT Versus Placebo | The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced disease. The primary evaluation criterion is clinical benefit response. | http://clinicaltrials.gov/show/NCT00332280 - Retrieved August 2011 | Auron Healthcare GmbH | The recruitment status of this study is unknown because the information has not been verified recently. | |
16 | 6 | http://clinicaltrials.gov/ct/show/NCT00861094 | Phase II-III Study Comparing Radiochemotherapy with the FOLFOX regimen Versus Radiochemotherapy with 5FU-Cisplatin (Herskovic Regimen) in First Line Treatment of Patients with Inoperable Oesophageal Cancer | This randomized phase II/III trial is studying radiation therapy and two different combination chemotherapy regimens to compare how well they work as first-line therapy in treating patients with esophageal cancer that cannot be removed by surgery. | http://clinicaltrials.gov/ct/show/NCT00861094 - Retrieved August 2011 | Federation Nationale des Centres de Lutte Contre le Cancer | National Cancer Institute | Currently recruiting |
17 | 7 | http://clinicaltrials.gov/show/NCT01249352 | A Phase II, Randomized, Controlled, Open-Label Study Comparing Standard Chemoradiation Versus Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer | The primary objective of this study is to assess the efficacy of nimotuzumab in combination with chemotherapy and radiotherapy for the treatment of locally advanced esophageal cancer, comparing it to that of the conventional treatment with radiation and chemotherapy. The secondary objective of this study is to assess the health-related quality of life for the nimotuzumab in combination with chemotherapy and radiotherapy regimen, compared to the standard chemoradiation regimen in the treatment of inoperable locally advanced esophageal cancer. | http://clinicaltrials.gov/show/NCT01249352 - Retrieved August 2011 | Eurofarma Laboratorios Ltda | Currently recruiting | |
18 | 8 | http://clinicaltrials.gov/show/NCT01348217 | Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus | Refer to clinical trials website. | http://clinicaltrials.gov/show/NCT01348217 - Retrieved August 2011 | Centre Georges Francois Leclerc | National Cancer Institute, France; UNICANCER-GI; SFRO: French Society of Radiation Oncology | Currently recruiting |
19 | 9 | http://clinicaltrials.gov/show/NCT01402180 | A Randomized Phase II Trial Evaluating The Addition Of Nimotuzumab To Chemoradiation For Patients With Esophageal Squamous Cell Carcinoma After Radical Esophagectomy Who Suffer With Lymph Nodes Recurrence | A randomized phase II tials to study whether it's benefit of adding Nimotuzumab to chemoradiation for patients with esophageal squamous cell carcinoma after radical esophagectomy who suffer with locoregional lymph nodes recurrence. | http://clinicaltrials.gov/show/NCT01402180 - Retrieved August 2011 | Fudan University | Shanghai Chest Hospital; Zhongshan Hospital; Fudan University; Shanghai Pulmonary Hospital; Shanghai Renji Hospital; Shanghai First People's Hospital | Currently recruiting |
20 | 10 | http://clinicaltrials.gov/show/NCT00193882 | A Randomised Phase III Study in Advanced Oesophageal Cancer to Compare Quality of Life and Palliation of Dysphagia in Patients Treated With Radiotherapy vs ChemoRadiotherapy | To compare the treatment of gullet cancer with radiotherapy alone and assess the advantage and toxicity of adding chemotherapy. The hypothesis to be tested is as follows: That the addition of chemotherapy to a short course of radiation treatment improves the proportion of patients who achieve relief of dysphagia and improves quality of life compared to radiation alone in patients with advanced oesophageal cancer. | http://clinicaltrials.gov/show/NCT00193882 - Retrieved August 2011 | Trans-Tasman Radiation Oncology Group (TROG) | National Health and Medical Research Council, Australia; NCIC Clinical Trials Group | Currently recruiting |
21 | 11 | http://clinicaltrials.gov/ct/show/NCT00655876 | A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery | This randomized phase III trial is comparing how well giving paclitaxel and cisplatin together with radiation therapy works with or without cetuximab in treating patients with locally advanced esophageal cancer. | http://clinicaltrials.gov/ct/show/NCT00655876 - Retrieved August 2011 | Radiation Therapy Oncology Group | National Cancer Institute | Currently recruiting |
22 | 12 | http://clinicaltrials.gov/show/NCT00665197 | Co-Ordinated Research Project on Improving Outcomes in Radiotherapy Using New Strategies of Treatment Delivery With Focus on Oesophageal Cancer | Hypothesis: In the management of advanced oesophageal cancer, to determine if a shorter regime of external beam radiotherapy (using higher daily doses, and combined with intraluminal high dose rate brachytherapy) is not inferior in the palliation of dysphagia than a more protracted course of external beam radiotherapy (using lower daily doses and combined with equal intraluminal high dose rate brachytherapy). | http://clinicaltrials.gov/show/NCT00665197 - Retrieved August 2011 | International Atomic Energy Agency | The recruitment status of this study is unknown because the information has not been verified recently. | |
23 | 13 | http://clinicaltrials.gov/show/NCT00680901 | A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib | This is an international multi-center trial that will enroll patients with locally advanced, unresectable, or metastatic gastric, esophageal, or gastro-esophageal junction cancer whose tumors have amplification of the ErbB2 (HER2) gene. The trial will investigate whether lapatinib, when added to the chemotherapy regimen, capecitabine plus oxaliplatin (CapeOx), extends the time to progression and overall survival. Tumor ErbB2 (HER2) status must be known before trial entry. CapeOx is administered to all patients, and patients will be randomly assigned to receive either lapatinib or placebo. | http://clinicaltrials.gov/show/NCT00680901 - Retrieved August 2011 | GlaxoSmithKline | Currently recruiting | |
24 | 14 | http://clinicaltrials.gov/show/NCT00760604 | A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Patients With Locally Advanced Esophageal Cancer | The purpose of this study is to test 2 different methods of surgery to remove cancer in the esophagus. This research is being done to see whether removing more tissue and lymph nodes surrounding the tumor in the esophagus (known as transthoracic en bloc esophagectomy) offers better control of the cancer than removing less tissue and lymph nodes (known as non-en bloc esophagectomy). | http://clinicaltrials.gov/show/NCT00760604 - Retrieved August 2011 | Weill Medical College of Cornell University | Currently recruiting | |
25 | 15 | http://clinicaltrials.gov/show/NCT00824785 | REAL 3 : A Randomised Open-labelled Multicentre Trial of the Efficacy of Epirubicin, Oxaliplatin and Capecitabine (EOX) With or Without Panitumumab in Previously Untreated Advanced Oesophago-gastric Cancer | To determine whether adding panitumumab, an antibody against the epidermal growth factor receptor (EGFR), to standard chemotherapy with epirubicin, oxaliplatin and capecitabine (EOX), improves the duration of survival of patients with advanced stomach and oesophageal cancer. | http://clinicaltrials.gov/show/NCT00824785 - Retrieved August 2011 | Royal Marsden NHS Foundation Trust | Currently recruiting | |
26 | 16 | http://clinicaltrials.gov/ct/show/NCT00978549 | Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma | This randomized phase II trial is studying symptom control given together with docetaxel to see how well it works compared with symptom control given without docetaxel in treating patients with relapsed esophageal cancer or stomach cancer. | http://clinicaltrials.gov/ct/show/NCT00978549 - Retrieved August 2011 | Cambridge University Hospitals NHS Foundation Trust | National Cancer Institute | The recruitment status of this study is unknown because the information has not been verified recently. |
27 | 17 | http://clinicaltrials.gov/show/NCT00937456 | Open vs Laparoscopically-assisted Esophagectomy for Cancer: A Multicentric Phase III Prospective Randomized Controlled Trial | To compare laparoscopically-assisted gastric mobilization versus open gastric mobilization in Ivor-Lewis esophagectomy for esophageal cancer, with open thoracic approach in the 2 arms. | http://clinicaltrials.gov/show/NCT00937456 - Retrieved August 2011 | University Hospital, Lille | Currently recruiting | |
28 | 18 | http://clinicaltrials.gov/show/NCT01053182 | A Phase Ⅲ Study of Respiratory Complications Associated With Esophagectomy Through Either Ivor-Lewis or Sweet Approach for the Treatment of Middle or Lower Third Intrathoracic Esophageal Carcinoma | Refer to clinical trials website. | http://clinicaltrials.gov/show/NCT01053182 - Retrieved August 2011 | Sichuan University | Currently recruiting | |
29 | 19 | http://clinicaltrials.gov/ct/show/NCT01243398 | Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Gefitinib (Iressa®) Versus Placebo in Esophageal Cancer Progressing After Chemotherapy | This randomized phase III trial is studying gefitinib to see how well it works compared with a placebo in treating patients with esophageal cancer that is progressing after chemotherapy. | http://clinicaltrials.gov/ct/show/NCT01243398 - Retrieved August 2011 | Oncology Clinical Trials Office at University of Oxford | National Cancer Institute | Currently recruiting |
30 | 20 | http://clinicaltrials.gov/show/NCT01361750 | The Effects of Gastric Tube on the Quality of Life and Nutritional Status After Ivor-Lewis Esophagectomy: A Randomized Control Trial and Physiological Study | This study is to investigate the effects of narrowed gastric tube on postoperative nutritional status and the quality of life in esophageal cancer patients treated with Ivor-Lewis esopagectomy in a 12-month follow-up period. | http://clinicaltrials.gov/show/NCT01361750 - Retrieved August 2011 | Peking University | Currently recruiting | |
31 | 21 | http://clinicaltrials.gov/show/NCT00493883 | Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors | The purpose of this study is to provide supervised access to treatment with TheraSphere® to eligible patients with primary and metastatic cancer and evaluate response to treatment, survival and toxicity. The study has the following objectives: •Provide supervised access to treatment with TheraSphere to eligible patients with primary and metastatic cancer to the liver. •Evaluate patient experience and toxicities associated with TheraSphere treatment. •Evaluate predisposing factors that may influence results and toxicity. | http://clinicaltrials.gov/show/NCT00493883 - Retrieved August 2011 | Southwestern Regional Medical Center | Currently recruiting | |
32 | 22 | http://clinicaltrials.gov/ct/show/NCT00544362 | Neoadjuvant Treatment for Operable Esophageal Cancer With 5-fluorouracil, Cisplatin, and Cetuximab and Concurrent Radiotherapy: Phase I/II Study | This phase I/II trial is studying the side effects and best dose of fluorouracil and cisplatin when given together with cetuximab and radiation therapy in treating patients with esophageal cancer that can be removed by surgery. | http://clinicaltrials.gov/ct/show/NCT00544362 - Retrieved August 2011 | Federation Francophone de Cancerologie Digestive | National Cancer Institute | The recruitment status of this study is unknown because the information has not been verified recently. |
33 | 23 | http://clinicaltrials.gov/show/NCT00667420 | A Pilot Study of Perioperative Panitumumab in Combination With Epirubicin, Oxaliplatin and Xeloda in Patients With Resectable Gastroesophageal Adenocarcinoma | A pilot study to determine the safety of using perioperative panitumumab with EOX in patients with adenocarcinoma of the esophagus and stomach. | http://clinicaltrials.gov/show/NCT00667420 - Retrieved August 2011 | Massachusetts General Hospital | Currently recruiting | |
34 | 24 | http://clinicaltrials.gov/show/NCT00669292 | Phase I/II Study of URLC10-177 and TTK-567, Novel Tumor Specific Epitope Peptides Restricted to HLA-A*2402 Derived From Tumor Associated Antigens, Combined With CpG7909, a TLR9 Agonist, in Patients With Advanced or Recurrent Esophageal Cancer. | This is a single institution phase I / II trial to evaluate the safety and efficacy of URLC10-177 and TTK-567 emulsified with Montanide ISA 51 in combination with different doses of CpG7909 in patients with advanced or recurrent esophageal cancer. | http://clinicaltrials.gov/show/NCT00669292 - Retrieved August 2011 | Wakayama Medical University | Human Genome Center, Institute of Medical Science, University of Tokyo | Currently recruiting |
35 | 25 | http://clinicaltrials.gov/show/NCT00915850 | Phase I/II Trial of Combination Chemotherapy With Docetaxel, Cisplatin and 5-FU for Unresectable Advanced Esophageal Cancer | This phase I/II study is being conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of a combination chemotherapy using docetaxel, cisplatin and 5-fluorouracil (DCF) in unresectable advanced esophageal cancer. The usefulness of the this regimen is evaluated by RECIST, time to progression and median survival time. | http://clinicaltrials.gov/show/NCT00915850 - Retrieved August 2011 | Wakayama Medical University | Currently recruiting | |
36 | 26 | http://clinicaltrials.gov/show/NCT00964080 | A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma | The ongoing study is a Phase II, open-label study to evaluate the efficacy of MBP-426 at a dose of 170 mg/m2 in combination therapy in patients with second line metastatic gastric, gastro-esophageal junction or esophageal adenocarcinoma. | http://clinicaltrials.gov/show/NCT00964080 - Retrieved August 2011 | Mebiopharm Co., Ltd | Currently recruiting | |
37 | 27 | http://clinicaltrials.gov/show/NCT01143545 | Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib as Adjuvant Therapy for Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas | Refer to clinical trials website. | http://clinicaltrials.gov/show/NCT01143545 - Retrieved August 2011 | National Cancer Institute | National Institutes of Health Clinical Center (CC) | Currently recruiting |
38 | 28 | http://clinicaltrials.gov/show/NCT01227772 | A Phase I/IIa Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer | Active vaccination with tumor specific antigens and VEGFR1 HLA-A24 epitopes can improve survival of patients with advanced GC. | http://clinicaltrials.gov/show/NCT01227772 - Retrieved August 2011 | National University Hospital, Singapore | This study is not yet open for participant recruitment. | |
39 | 29 | http://clinicaltrials.gov/show/NCT01325441 | A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | This is an open label, single arm dose escalation study of BBI608 in combination with paclitaxel in patients with advanced malignancies. | http://clinicaltrials.gov/show/NCT01325441 - Retrieved August 2011 | Boston Biomedical, Inc | Currently recruiting | |
40 | 30 | http://clinicaltrials.gov/show/NCT00149006 | Tumor-Selective and Systemic Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With rIL-2 and Non-Myeloablative Stem Cell Transplantation | The present protocol is designed to investigate the potential application of allogeneic cell-mediated immunotherapy in metastatic solid tumors similarly to the well established graft versus leukemia (GVL) effects in patients with hematologic malignancies. Patients with metastatic solid tumors resistant to conventional modalities will be eligible to participate in a treatment program based on the administration of non-myeloablative immunotherapy (i.e. fludarabine, Cytoxan) followed by interferon injections; subsequently the patients will be treated with mismatched alloreactive donor lymphocytes activated in vitro and in vivo with rIL-2. The aim of this study is based on the recognition of foreign tumor cell surface alloantigens. | http://clinicaltrials.gov/show/NCT00149006 - Retrieved August 2011 | Hadassah Medical Organization | The recruitment status of this study is unknown because the information has not been verified recently. | |
41 | 31 | http://clinicaltrials.gov/show/NCT00197431 | Pharmacokinetic and Pharmacodynamic Study of S-1 and Its Effects in Patients With the Digestive Organ Cancer With Reference to Genetic Polymorphism and Activity of CYP2A6 and DPD | S-1 is a novel oral fluorouracil antitumor drug that consists of tegafur which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydropyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. 5-FU is metabolized by CYP2A6 and DPD. In this study, the researchers investigate the influences of differences in activities of CYP2A6 and DPD on pharmacokinetics and pharmacodynamics of S-1 and clinical outcomes in digestive organ cancer patients treated with S-1. | http://clinicaltrials.gov/show/NCT00197431 - Retrieved August 2011 | Hamamatsu University | The recruitment status of this study is unknown because the information has not been verified recently. | |
42 | 32 | http://clinicaltrials.gov/show/NCT00183872 | Phase II Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma | Refer to clinical trials website. | http://clinicaltrials.gov/show/NCT00183872 - Retrieved August 2011 | USC/Norris Comprehensive Cancer Center | Sanofi-Aventis | Currently recruiting |
43 | 33 | http://clinicaltrials.gov/show/NCT00183898 | Phase II Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer | Refer to clinical trials website. | http://clinicaltrials.gov/show/NCT00183898 - Retrieved August 2011 | USC/Norris Comprehensive Cancer Center | Sanofi-Aventis; Roche Global Development; Bristol-Myers Squibb | Currently recruiting |
44 | 34 | http://clinicaltrials.gov/ct/show/NCT00381706 | Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer | This randomized phase II trial is studying three different combination chemotherapy regimens to compare how well they work when given together with cetuximab in treating patients with metastatic esophageal cancer or gastroesophageal junction cancer. | http://clinicaltrials.gov/ct/show/NCT00381706 - Retrieved August 2011 | Cancer and Leukemia Group B | National Cancer Institute (NCI); Eastern Cooperative Oncology Group | The recruitment status of this study is unknown because the information has not been verified recently. |
45 | 35 | http://clinicaltrials.gov/ct/show/NCT00403468 | A Phase II Study of Docetaxel, Cisplatin and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma | This phase II trial is studying how well giving combination chemotherapy together with bevacizumab works in treating patients with recurrent, unresectable, or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal cancer. | http://clinicaltrials.gov/ct/show/NCT00403468 - Retrieved August 2011 | Memorial Sloan-Kettering Cancer Center | National Cancer Institute | The recruitment status of this study is unknown because the information has not been verified recently. |
46 | 36 | http://clinicaltrials.gov/show/NCT00420394 | Phase II Study of Preoperative Chemotherapy and Postoperative Chemo-Radiation for Newly Diagnosed, Potentially Resectable Gastric Cancer | To evaluate feasibility and safety of combination of preoperative chemotherapy and postoperative chemoradiation for locally advanced adenocarcinoma of stomach and gastroesophageal cancer. | http://clinicaltrials.gov/show/NCT00420394 - Retrieved August 2011 | Soroka University Medical Center | The recruitment status of this study is unknown because the information has not been verified recently. | |
47 | 37 | http://clinicaltrials.gov/show/NCT00447330 | A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas | The purpose of this study is to evaluate the progression free survival of capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) in previously untreated metastatic esophagogastric adenocarcinomas. | http://clinicaltrials.gov/show/NCT00447330 - Retrieved August 2011 | Duke University | Hoffmann-La Roche; Sanofi-Aventis; Genentech | Currently recruiting |
48 | 38 | http://clinicaltrials.gov/show/NCT00454519 | Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial | Refer to clinical trials website. | http://clinicaltrials.gov/show/NCT00454519 - Retrieved August 2011 | Wuhan University | NPO Organization to Support Peritoneal Dissemination Treatment; Kishiwada Tokushukai Hospital; Kusatsu General Hospital; Ikeda Hospital | The recruitment status of this study is unknown because the information has not been verified recently. |
49 | 39 | http://clinicaltrials.gov/show/NCT00515411 | A Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Patients With Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma | Chemotherapy given together is a standard way to treat your cancer. One standard treatment includes a combination of docetaxel, cisplatin, and fluorouracil. However, the original combination of these three drugs can cause many side effects. This study is being done to find out if these three drugs can be given at lower doses more often, with fewer side effects and still maintain the same benefit as the standard way of giving this three drug combination. If your tumor overexpresses a protein called Her2, you are also eligible to receive trastuzumab with chemotherapy. Trastuzumab is a medicine that has been approved by the US Food and Drug Administration for the treatment of Her2 positive breast cancer. Trastuzumab is now also a standard treatment in combination with chemotherapy for the treatment of Her2 positive stomach cancer. If your tumor is Her2 positive, you would receive the modified administration schedule of docetaxel, cisplatin, and fluorouracil with trastuzumab. | http://clinicaltrials.gov/show/NCT00515411 - Retrieved August 2011 | Memorial Sloan-Kettering Cancer Center | Sanofi-Aventis; Roche/Genetech; City of Hope National Medical Center; Piedmont Hopsital Research Institute; Medical College of Wisconsin; Queens Health Network; Weill Medical College of Cornell University; Memorial Cancer Institute, Florida; University of Pittsburgh; Long Island Jewish Medical Center; Nebraska Cancer Specialists Methodist Estabrook Cancer Center | Currently recruiting |
50 | 40 | http://clinicaltrials.gov/show/NCT00601705 | A Phase II Trial of Induction Chemotherapy With Epirubicin, Oxaliplatin and Fluorouracil (EOF) Followed by Esophagogastrectomy and Post-operative Concurrent Chemoradiotherapy With Fluorouracil and Cisplatin, in Patients With Loco-regionally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction and Gastric Cardia | This phase II trial is studying how well giving combination chemotherapy, surgery, and radiation therapy works in treating patients with locoregionally advanced cancer of the esophagus, gastroesophageal junction, or stomach. | http://clinicaltrials.gov/show/NCT00601705 - Retrieved August 2011 | Case Comprehensive Cancer Center | National Cancer Institute | Currently recruiting |
51 | 41 | http://clinicaltrials.gov/ct/show/NCT00637637 | Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study | This randomized phase II trial is studying external-beam radiation therapy alone to see how well it works compared to external-beam radiation therapy given together with indinavir and ritonavir in treating patients with brain metastases. | http://clinicaltrials.gov/ct/show/NCT00637637 - Retrieved August 2011 | Oncology Institute of Southern Switzerland | National Cancer Institute | The recruitment status of this study is unknown because the information has not been verified recently. |
52 | 42 | http://clinicaltrials.gov/show/NCT00633789 | A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors | The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on treatment. Those in which it is unclear will be randomized to continue or withdraw treatment to determine whether that benefit is related to brivanib. | http://clinicaltrials.gov/show/NCT00633789 - Retrieved August 2011 | Bristol-Myers Squibb | Currently recruiting | |
53 | 43 | http://clinicaltrials.gov/ct/show/NCT00659113 | A Phase II Trial of a TS-1/Cisplatin Based Definitive Chemoradiotherapy for Resectable Esophageal Cancer | This phase II trial is studying how well giving S-1 and cisplatin together with radiation therapy works in treating patients with stage IIA, stage III, or stage IVA esophageal cancer that can be removed by surgery. | http://clinicaltrials.gov/ct/show/NCT00659113 - Retrieved August 2011 | Yonsei University | National Cancer Institute | The recruitment status of this study is unknown because the information has not been verified recently. |
54 | 44 | http://clinicaltrials.gov/show/NCT00673673 | Phase II Study of FOLFOX With Bevacizumab (Avastin(TM)) in Metastatic or Unresectable Gastroesophageal and Gastric Cancer | This is a Phase II open-label study to determine the anti-tumor efficacy and tolerability of FOLFOX in combination with bevacizumab (Avastin(TM))in patients with metastatic or unresectable gastroesophageal and gastric adenocarcinoma. Our primary objective is to determine the time to progression in patients treated with FOLFOX in combination with bevacizumab. | http://clinicaltrials.gov/show/NCT00673673 - Retrieved August 2011 | Yale University | Genentech | The recruitment status of this study is unknown because the information has not been verified recently. |
55 | 45 | http://clinicaltrials.gov/ct/show/NCT00702884 | A Mechanistic Radiographic and Biologic Phase 2 Single Agent Study of Sunitinib Malate in Relapsed/Refractory Esophageal and Gastroesophageal Cancers | This phase II trial is studying how well sunitinib works in treating patients with relapsed or refractory esophageal or gastroesophageal junction cancer. | http://clinicaltrials.gov/ct/show/NCT00702884 - Retrieved August 2011 | Arthur G. James Cancer Hospital & Richard J. Solove Research Institute | National Cancer Institute | The recruitment status of this study is unknown because the information has not been verified recently. |
56 | 46 | http://clinicaltrials.gov/show/NCT00763646 | Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma | The primary purpose of the study is to determine the impact of chemotherapy on the ability of your surgeon to completely remove the cancer as well as the impact on your survival. Furthermore the investigators will be assessing the side effects of this chemotherapy strategy. Finally the investigators will determine the ability of specialized imaging technology (PET scan) to document and predict the response of the tumor to this chemotherapy. Standard therapy for patients with your condition usually consists of surgery (removal of the tumor) followed by combination chemotherapy and radiotherapy. More recently, standard options available to patients with cancer of the stomach or lower esophagus have been expanded to include chemotherapy without radiotherapy prior to and following surgery. While it is believed that chemotherapy prior to surgery is a good option for patients with stomach, it is not known what is the optimal chemotherapy regimen to offer patients prior to surgery to improve the likelihood of cure while limiting side-effects to patients. | http://clinicaltrials.gov/show/NCT00763646 - Retrieved August 2011 | McGill University | The recruitment status of this study is unknown because the information has not been verified recently. | |
57 | 47 | http://clinicaltrials.gov/show/NCT00765570 | Treatment of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy A Phase II Randomized Trial | Expand clinical literature on the use of Grid radiation with conventional external beam therapy. Vast majority of therapy is for palliative care to provide relief from pain, but has also shown a reduction in the size of tumor mass. | http://clinicaltrials.gov/show/NCT00765570 - Retrieved August 2011 | Summa Health System | Currently recruiting | |
58 | 48 | http://clinicaltrials.gov/ct/show/NCT00806949 | A Randomised Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer - The ELECT Trial. | This randomized phase II trial is studying how well giving epirubicin together with oxaliplatin and capecitabine works compared with giving docetaxel together with oxaliplatin in treating patients with advanced esophageal cancer, gastroesophageal junction cancer, or stomach cancer. | http://clinicaltrials.gov/ct/show/NCT00806949 - Retrieved August 2011 | All Ireland Cooperative Oncology Research Group | National Cancer Institute | The recruitment status of this study is unknown because the information has not been verified recently. |
59 | 49 | http://clinicaltrials.gov/show/NCT00816634 | A Randomized Phase II Trial of Capecitabine Plus Cisplatin (XP) Versus Capecitabine Plus Paclitaxel (XT) as a First-line Treatment for Advanced or Recurrent Esophageal Squamous Cell Carcinoma | Refer to clinical trials website. | http://clinicaltrials.gov/show/NCT00816634 - Retrieved August 2011 | Samsung Medical Center | Currently recruiting | |
60 | 50 | http://clinicaltrials.gov/show/NCT00836277 | Phase II Study of Irinotecan and Panitumumab as Second-Line Therapy for Patients With Advanced Esophageal Adenocarcinoma | This study proposes a single-arm, phase II study of irinotecan with panitumumab as second-line therapy for patients with advanced esophageal adenocarcinoma. Efficacy will be assessed by response rate, with an exploratory outcome endpoint of time to progression (as panitumumab may result in prolonged stable disease). In addition to the usual safety assessments, molecular correlates will be carried out in order to search for pharmacodynamic and pharmacogenomic features that may correlate with response. Measures of host/patient immune function will be assessed by evaluating the relationship between Fc receptor polymorphisms and response in patients treated with panitumumab. Measures of EGFR protein and phosphoprotein expression by immunohistochemical- (IHC-) staining, K-ras mutation status1 and reverse-phase protein arrays (RPPA) and EGFR gene amplification by fluorescence in situ hybridization (FISH) will be assessed as exploratory correlates. | http://clinicaltrials.gov/show/NCT00836277 - Retrieved August 2011 | University of Pittsburgh | Amgen | Currently recruiting |
61 | 51 | http://clinicaltrials.gov/show/NCT00855452 | rIL-2 Activated Allogeneic Lymphocytes for the Induction of Graft Versus Tumor Effect (GVT) in Metastatic Solid Tumors | Refer to clinical trials website. | http://clinicaltrials.gov/show/NCT00855452 - Retrieved August 2011 | Hadassah Medical Organization | The recruitment status of this study is unknown because the information has not been verified recently. | |
62 | 52 | http://clinicaltrials.gov/show/NCT00917462 | Phase II Trial of Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer | Sorafenib is a drug being studied for the treatment of cancer. Sorafenib has been shown to block certain proteins on the surface of some cancer cells called "growth factor receptors." Blocking these growth factor receptors can slow or stop cancer cell growth. Sorafenib is also known as Nexavar®. It has been studied in other types of cancers, including kidney cancer, and has been approved by the Food and Drug Administration (FDA) for treating advanced kidney cancer. Because it is not approved by the FDA for treating esophageal cancer, it is considered an experimental treatment. The purpose of this study is to determine what effects sorafenib has on advanced esophageal cancer. These effects include whether sorafenib can shrink the tumor or slow down its growth and what side effects sorafenib will have on the tumor. | http://clinicaltrials.gov/show/NCT00917462 - Retrieved August 2011 | Memorial Sloan-Kettering Cancer Center | Bayer | Currently recruiting |
63 | 53 | http://clinicaltrials.gov/show/NCT00942526 | The Correlation of Oral Anti-Infective Agent With Anastomotic Leakage in Reconstruction Surgery for Esophageal Cancer | Anastomotic leakage is still to be a major cause of considerable morbidity and mortality after esophagectomy and gastric pull up for esophageal carcinoma. Risk factor analyses of anastomotic leakage, including blood supply, graft tension, and comorbidity, have been performed, but few studies have produced strategies that have improved operative results. This study will be performed to identify prognostic variables that might be used to develop a strategy for optimizing outcomes after esophagogastrectomy. | http://clinicaltrials.gov/show/NCT00942526 - Retrieved August 2011 | National Taiwan University Hospital | The recruitment status of this study is unknown because the information has not been verified recently. | |
64 | 54 | http://clinicaltrials.gov/show/NCT00985192 | A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach | This phase II trial is studying how well everolimus works in treating patients with previously treated unresectable or metastatic esophageal cancer or stomach cancer. | http://clinicaltrials.gov/show/NCT00985192 - Retrieved August 2011 | Translational Oncology Research International | National Cancer Institute; University of California, Los Angeles | Currently recruiting |
65 | 55 | http://clinicaltrials.gov/show/NCT00995358 | Phase II Multicenter Trial of Peptide Vaccination Therapy Using Novel Cancer Testis Antigens for Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma | The purpose of this study is to evaluate overall survival and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC). | http://clinicaltrials.gov/show/NCT00995358 - Retrieved August 2011 | University of Yamanashi | Human Genome Center, Institute of Medical Science, University of Tokyo | Currently recruiting |
66 | 56 | http://clinicaltrials.gov/show/NCT01020630 | A Randomized, Placebo-controlled Phase II Trial Investigating SUNITINIB Versus Placebo in Patients With Chemorefractory Advanced Adenocarcinoma of the Stomach or Lower Esophagus Treated With Chemotherapy FOLFIRI | This trial will be conducted to evaluate the efficacy, safety and tolerability of SUNITINIB as add-on therapy with a widely used second-line palliative FOLFIRI chemotherapy in patients with chemo-refractory advanced or metastatic adenocarcinoma of stomach or lower esophagus (mGC). There is a clear scientific rationale for the use of Sunitinib to treat patients with mGC. Despite recent therapeutic advances, the median overall survival (OS) in patients with mG is still ≤ 12 months. Therefore, newer agents with novel mechanisms of action are desperately needed for treatment of these patients. | http://clinicaltrials.gov/show/NCT01020630 - Retrieved August 2011 | Johannes Gutenberg University Mainz | Currently recruiting | |
67 | 57 | http://clinicaltrials.gov/show/NCT01034189 | A Phase II Study of Combining Cetuximab Plus Twice Weekly Paclitaxel/Cisplatin Concurrent Chemoradiotherapy (TP-CCRT) Followed With or Without Esophagectomy for Loco-regional Esophageal Squamous Cell Carcinoma (ESCC) | We hypothesize that the addition of cetuximab to twice weekly paclitaxel/cisplatin concurrent chemoradiotherapy (TP-CCRT) as the adjunctive therapy before esophagectomy or as a definitive CRT would improve the therapeutic efficacy of TP-CCRT in patients with loco-regional esophageal squamous cell carcinoma (ESCC). | http://clinicaltrials.gov/show/NCT01034189 - Retrieved August 2011 | National Taiwan University Hospital | Currently recruiting | |
68 | 58 | http://clinicaltrials.gov/show/NCT01034332 | A Phase II Study With One-cycle Weekly TP-HDFL Followed by Twice Weekly TP-CCRT and Esophagectomy for Locally Advanced Esophageal Cancer | We hypothesize that one-cycle induction chemotherapy may also help to identify chemo-responsive esophageal cancer patients who are highly treatable by definitive CCRT. | http://clinicaltrials.gov/show/NCT01034332 - Retrieved August 2011 | National Taiwan University Hospital | Currently recruiting | |
69 | 59 | http://clinicaltrials.gov/show/NCT01044420 | mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial | There are few studies about 2nd line treatment in advanced esophageal carcinoma(AEC), some showed that irinotecan may be effective. The investigators previous study has shown the efficacy and safety of paclitaxel/cisplatin as 1st line treatment, so in this phase II study, the investigators would like to observe the efficacy and safety of Irinotecan/5FU/leucovorin as 2nd line treatment if AEC after failure to 1st treatment of PTX/DDP. | http://clinicaltrials.gov/show/NCT01044420 - Retrieved August 2011 | Peking University | Currently recruiting | |
70 | 60 | http://clinicaltrials.gov/show/NCT01051765 | Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial | Irinotecan, as one new agent used in advanced esophageal carcinoma, has been shown to be effective and safe in western studies. Different with westerns, squamous carcinoma is the main pathological type in china patients. The investigators then initiated a prospective phase II clinical trial with irinotecan/cisplatin as the 1st line treatment in advanced esophageal carcinoma to observe the efficacy and safety of the combination. | http://clinicaltrials.gov/show/NCT01051765 - Retrieved August 2011 | Peking University | Currently recruiting | |
71 | 61 | http://clinicaltrials.gov/ct/show/NCT01142388 | Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer | This randomized phase II trial is studying giving paclitaxel and cixutumumab together to see how well they work compared to paclitaxel alone in treating patients with metastatic esophageal cancer or gastroesophageal junction cancer. | http://clinicaltrials.gov/ct/show/NCT01142388 - Retrieved August 2011 | Eastern Cooperative Oncology Group | National Cancer Institute | Currently recruiting |
72 | 62 | http://clinicaltrials.gov/show/NCT01129206 | Phase II Study of Pralatrexate and Docetaxel in Patients With Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-based Therapy. | This phase II trial is studying how well giving pralatrexate together with docetaxel works in treating patients with stage IV esophageal or gastroesophageal cancer who have failed platinum-based therapy. | http://clinicaltrials.gov/show/NCT01129206 - Retrieved August 2011 | Ohio State University Comprehensive Cancer Center | National Comprehensive Cancer Network | Currently recruiting |
73 | 63 | http://clinicaltrials.gov/show/NCT01145404 | Lapatinib Versus Lapatinib With Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A Randomized Phase II Trial | Refer to clinical trials website. | http://clinicaltrials.gov/show/NCT01145404 - Retrieved August 2011 | National Center for Tumor Diseases, Heidelberg | Currently recruiting | |
74 | 64 | http://clinicaltrials.gov/ct/show/NCT01158287 | Phase II Study of Single Agent Sorafenib in the Treatment of Relapsed Esophageal/Gastric Adenocarcinoma in Platinum Pre-Treated Patients | This phase II trial is studying how well sorafenib tosylate works in treating patients with relapsed esophageal cancer and/or stomach cancer. | http://clinicaltrials.gov/ct/show/NCT01158287 - Retrieved August 2011 | All Ireland Cooperative Oncology Research Group | National Cancer Institute | Currently recruiting |
75 | 65 | http://clinicaltrials.gov/show/NCT01167114 | A Phase 2 Clinical Trial of STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancers | In this research study, the investigators are looking to see how effective STA-9090 is in treating esophagogastric cancer. The investigators will also evaluate the side effects of STA-9090, and examine the relationship between the presence of HSP-90 and how well study participants respond to STA-9090. STA-9090 works by blocking a protein in tumor cells called HSP90, which is thought to play a role in tumor growth. By interfering with this protein's function, STA-9090 may help kill tumor cells. This drug has been used in other research studies and information from those other research studies suggests that this agent may help to slow tumor growth in esophagogastric cancer. | http://clinicaltrials.gov/show/NCT01167114 - Retrieved August 2011 | Massachusetts General Hospital | Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Synta Pharmaceuticals Corp. | Currently recruiting |
76 | 66 | http://clinicaltrials.gov/show/NCT01174121 | A Phase II Study Using Short-Term Cultured, CD8+-Enriched Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers | Refer to clinical trials website. | http://clinicaltrials.gov/show/NCT01174121 - Retrieved August 2011 | National Cancer Institute | National Institutes of Health Clinical Center (CC) | Currently recruiting |
77 | 67 | http://clinicaltrials.gov/show/NCT01178944 | Pralatrexate in Combination With Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial With Predictive Molecular Correlates | Pralatrexate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pralatrexate and oxaliplatin together may kill more tumor cells. PURPOSE: This phase II trial is studying how well pralatrexate and oxaliplatin work in treating patients with unresectable or metastatic esophageal, stomach, or gastroesophageal junction cancer. | http://clinicaltrials.gov/show/NCT01178944 - Retrieved August 2011 | Roswell Park Cancer Institute | National Comprehensive Cancer Network | Currently recruiting |
78 | 68 | http://clinicaltrials.gov/show/NCT01182610 | A Phase II Study of Pre-operative Panitumumab, Paclitaxel, Carboplatin and Continuous Infusion 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma | This is an open-label, Phase II, single-stage study evaluating the use of panitumumab, paclitaxel, carboplatin and 5FU as an induction regimen in subjects with gastroesophageal adenocarcinoma. The expectation is that this combination will both increase potential overall survival by incorporating novel biologic therapy in the neoadjuvant setting and decrease potential surgical mortality by eliminating pre-operative radiation therapy. | http://clinicaltrials.gov/show/NCT01182610 - Retrieved August 2011 | Accelerated Community Oncology Research Network | Amgen | Currently recruiting |
79 | 69 | http://clinicaltrials.gov/show/NCT01197885 | International, Multicenter, Open-label, Phase II Study to Investigate the Efficacy and Safety of Multiple Doses of IMAB362 in Patients With Advanced Adenocarcinoma of the Stomach or the Lower Esophagus | IMAB362 is a monoclonal antibody specific for gastric or lower esophageal adenocarcinoma. Preclinically IMAB362 was shown to inhibit tumor growth and to kill cancer cells by indirect (complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity) and direct mechanisms (antiproliferative and proapoptotic effects). The aim of this phase II study is to establish efficacy and safety of multiple doses of IMAB362 as monotherapy in patients suffering from metastatic, refractory or recurrent adenocarcinoma of the stomach or the lower esophagus. | http://clinicaltrials.gov/show/NCT01197885 - Retrieved August 2011 | Ganymed Pharmaceuticals AG | Currently recruiting | |
80 | 70 | http://clinicaltrials.gov/show/NCT01232374 | A Clinical Study of Nimotuzumab in Combination With Concurrent Chemotherapy and Radiation for Patients With Local Advanced Esophageal Squamous Cell Carcinoma | Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate Nimotuzumab in different indications. Nimotuzumab has been approved to treat squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal carcinoma in different countries. The clinical phase I study of the combination of Nimotuzumab administered concurrently with chemo-irradiation in patients with local advanced esophageal squamous cell carcinoma (LAFSCC) has shown the safety and the potential efficacy of Nimotuzumab. The concurrent trial is a clinical phase II trial designed to assess the efficacy of the combination of Nimotuzumab administered concurrently with chemo-radiotherapy in patients with LAFSCC, and to further investigate its side-effect and toxicity. | http://clinicaltrials.gov/show/NCT01232374 - Retrieved Augusut 2011 | Biotech Pharmaceutical Co., Ltd. | Currently recruiting | |
81 | 71 | http://clinicaltrials.gov/ct/show/NCT01260701 | A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer | This phase II clinical trial is studying how well MK2206 works in treating patients with advanced gastric or gastroesophageal junction cancer. | http://clinicaltrials.gov/ct/show/NCT01260701 - Retrieved August 2011 | Southwest Oncology Group | National Cancer Institute | Currently recruiting |
82 | 72 | http://clinicaltrials.gov/show/NCT01246960 | Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach | The purpose of this study is to determine whether ramucirumab when used in conjunction with chemotherapy treatment can help patients with stomach, esophagus and gastroesophageal cancer. | http://clinicaltrials.gov/show/NCT01246960 - Retrieved August 2011 | Eli Lilly and Company | Currently recruiting | |
83 | 73 | http://clinicaltrials.gov/show/NCT01248299 | A Multicenter Randomized Phase II Study to Evaluate the Benefit of Chemotherapy Plus Best Supportive Care (BSC) Versus BSC in Patients With Metastatic Oesophageal Cancer of Squamous Cell-type Who Have Not Experienced a Disease Progression or Unacceptable Toxicity After a 6-weeks Chemotherapy Course . | Interest of continuing systemic chemotherapy or not , after a short initial treatment (6 weeks) in patients who are in response or stable disease("Discontinuation design ")of patients with metastatic oesophageal cancer of squamous cell type. The secondary aims would be to study : toxicity, the overall survival rate, a study of costs and quality of life. | http://clinicaltrials.gov/show/NCT01248299 - Retrieved August 2011 | Centre Oscar Lambret | Currently recruiting | |
84 | 74 | http://clinicaltrials.gov/show/NCT01262183 | A Randomised Phase II Study of Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus | Refer to clinical trials website. | http://clinicaltrials.gov/show/NCT01262183 - Retrieved Augst 2011 | Radboud University | Currently recruiting | |
85 | 75 | http://clinicaltrials.gov/show/NCT01267578 | Phase II Multicenter Trial of Peptide Vaccination Therapy Using Novel Cancer Testis Antigens (STF-II) for Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma | The purpose of this study is to evaluate overall survival and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens (STF-II) for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma. | http://clinicaltrials.gov/show/NCT01267578 - Retrieved August 2011 | University of Yamanashi | Human Genome Center, Institute of Medical Science, University of Tokyo | Currently recruiting |
86 | 76 | http://clinicaltrials.gov/show/NCT01291823 | A Phase II Study of Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer | Elderly patients with esophageal cancer will receive thoracic radiation therapy 54-60Gy over 30 fractions, and concurrent with Gefitinib. | http://clinicaltrials.gov/show/NCT01291823 - Retrieved August 2011 | Zhejiang Cancer Hospital | Currently recruiting | |
87 | 77 | http://clinicaltrials.gov/show/NCT01336049 | Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial | Nimotuzumab, as one new agent used in advanced esophageal carcinoma, has been shown to be effective and safe in some studies with head-neck cancers. Advanced esophageal carcinoma have poor prognosis and majority of patients resistant to chemotherapy in China. In the investigators phase II clinical trial proceeded before,the combination of paclitaxel with cisplatin showed good tolerance and efficacy to esophageal carcinoma. The investigators then initiated a prospective phase II clinical trial with Nimotuzumabplus paclitaxel/cisplatin as the 1st line treatment in advanced esophageal carcinoma to observe the efficacy and safety of the combination. | http://clinicaltrials.gov/show/NCT01336049 - Retrieved August 2011 | Peking University | Currently recruiting | |
88 | 78 | http://clinicaltrials.gov/show/NCT01362127 | Adjuvant Treatment of Cancer of the Esophagus or Cardia Before Resection With Curative Intent. Comparative Study Between Chemotherapy and Radiochemotherapy | The purpose of this randomized study is to clarify if neoadjuvant radiochemotherapy gives a higher degree of complete histological response than neoadjuvant chemotherapy before surgery in patients undergoing treatment for cancer of the esophagus or cardia. | http://clinicaltrials.gov/show/NCT01362127 - Retrieved August 2011 | Karolinska University Hospital | Umea University Hospital; University Hospital Orebro; Sahlgrenska University Hospital, Sweden; Ullevaal University Hospital; Haukeland University Hhospital, Bergen; Oslo University Hospital; St. Olavs Hospital; Malarhospital Eskilstuna | Currently recruiting |
89 | 79 | http://clinicaltrials.gov/show/NCT01365130 | A Phase II Study Of Cabazitaxel For Metastatic Gastroesophageal Adenocarcinomas That Have Relapsed After At Least One Line Of Chemotherapy | The purpose of this study is to evaluate the effectiveness of Cabazitaxel, as well as safety and side effects for patients with advanced gastroesophageal cancer | http://clinicaltrials.gov/show/NCT01365130 - Retrieved August 2011 | Brown University | Department of Veterans Affairs; Roger Willliams Medical Center; Rhode Island Hospital; The Miriam Hospital | This study is not yet open for participant recruitment. |
90 | 80 | http://clinicaltrials.gov/show/NCT01395537 | Phase II Pilot Study of Lapatinib in Combination With Carboplatin and Paclitaxel in the Treatment of Recurrent/Metastatic Adenocarcinoma of the Esophagus and Gastroesophageal Junction (GEJ) | Lapatinib is currently approved for HER2 positive metastatic breast cancer in combination with capecitabine or letrozole. It is hoped that by giving lapatinib and carboplatin and paclitaxel together, their combined effects will further slow or stop the cancer cells from growing. | http://clinicaltrials.gov/show/NCT01395537 - Retrieved August 2011 | Case Comprehensive Cancer Center | Currently recruiting | |
91 | 81 | http://clinicaltrials.gov/ct/show/NCT00098644 | Phase I Study Of Sequential Depsipeptide/Flavopiridol Infusion for Malignancies Involving Lungs, Esophagus, Pleura or Mediastinum | Refer to clinical trials website. | http://clinicaltrials.gov/ct/show/NCT00098644 - Retrieved August 2011 | National Cancer Institute | The recruitment status of this study is unknown because the information has not been verified recently. | |
92 | 82 | http://clinicaltrials.gov/show/NCT00462033 | Induction Therapy for Locally Advanced, Resectable Cancer of the Esophagus, GE Junction and Gastric Cardia: A Phase I Trial ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil and XRT Followed by Surgery | How well ZD6474 is tolerated with standard chemotherapy and radiation therapy. | http://clinicaltrials.gov/show/NCT00462033 - Retrieved August 2011 | Thomas Jefferson University | The recruitment status of this study is unknown because the information has not been verified recently. | |
93 | 83 | http://clinicaltrials.gov/show/NCT00524186 | Phase I Study of Sunitinib With FOLFIRI (Irinotecan, 5-Fluorouracil and Leucovorin) for Advanced Gastroesophageal Cancers | This phase I trial is studying the side effects and best dose of sunitinib when given together with irinotecan, fluorouracil, and leucovorin in treating patients with advanced stomach cancer or gastroesophageal cancer. | http://clinicaltrials.gov/show/NCT00524186 - Retrieved August 2011 | Roswell Park Cancer Institute | Currently recruiting | |
94 | 84 | http://clinicaltrials.gov/show/NCT00632333 | Phase I Study of Chemoradiation Therapy With Epitope Peptide Vaccine Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer | The purpose of this study is to evaluate the safety and immune response of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 in combination with chemotherapy (CDDP, 5-FU) plus radiation therapy in treating patients with unresectable, advanced or recurrent esophageal cancer. | http://clinicaltrials.gov/show/NCT00632333 - Retrieved August 2011 | Teikyo University | Human Genome Center, Institute of Medical Science, University of Tokyo | Currently recruiting |
95 | 85 | http://clinicaltrials.gov/show/NCT00666991 | A Phase 1 Study of Intraperitoneal Nanoparticle Paclitaxel in Patients With Peritoneal Malignancies | The purpose of this study is to evaluate the safety, pharmacokinetics and preliminary efficacy of an intraperitoneally administered suspension of nanoparticulate paclitaxel in patients with refractory malignancies principally confined to the peritoneal cavity. | http://clinicaltrials.gov/show/NCT00666991 - Retrieved August 2011 | CritiTech, Inc. | University of Kansas Medical Center Research Institute, Inc.; Beckloff Associates, Inc. | Currently recruiting |
96 | 86 | http://clinicaltrials.gov/show/NCT00682227 | Phase I Study of Peptide Vaccination Therapy Using Novel Cancer Testis Antigens for Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma | The purpose of this study is to evaluate the safety and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma. | http://clinicaltrials.gov/show/NCT00682227 - Retrieved August 2011 | University of Yamanashi | Human Genome Center, Institute of Medical Science, University of Tokyo | The recruitment status of this study is unknown because the information has not been verified recently. |
97 | 87 | http://clinicaltrials.gov/show/NCT01172028 | Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients | This phase I trial is studying the side effects and best dose of giving pemetrexed disodium and docetaxel together in treating patients with advanced solid tumors. | http://clinicaltrials.gov/show/NCT01172028 - Retrieved August 2011 | University of Arizona | National Cancer Institute | Currently recruiting |
98 | 88 | http://clinicaltrials.gov/show/NCT00701857 | Phase I Study of Concomitant Pemetrexed and CDDP plus Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal (GEJ) Carcinomas | This phase I trial is studying the side effects and best dose of pemetrexed when given together with cisplatin and radiation therapy in treating patients with stage III or stage IV esophageal cancer or gastroesophageal junction cancer. | http://clinicaltrials.gov/show/NCT00701857 - Retrieved August 2011 | University of Arizona | National Cancer Institute | Currently recruiting |
99 | 89 | http://clinicaltrials.gov/show/NCT00813423 | Autophagic Modulation With Anti-Angiogenic Therapy in Patients With Advanced Malignancies: A Phase I Trial of Sunitinib and Hydroxychloroquine | This phase I trial is studying the side effects and best dose of sunitinib when given together with hydroxychloroquine in treating patients with advanced solid tumors that have not responded to chemotherapy. | http://clinicaltrials.gov/show/NCT00813423 - Retrieved August 2011 | University of Medicine and Dentistry New Jersey | National Cancer Institute | Currently recruiting |
100 | 90 | http://clinicaltrials.gov/show/NCT00909402 | Phase 1b Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination With Cisplatin and Capecitabine as First-Line Therapy in Patients With Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas | The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923 administered in combination with Cisplatin and Capecitabine as first-line therapy in subjects with inoperable metastatic gastric, gastroesophageal or esophageal adenocarcinomas. | http://clinicaltrials.gov/show/NCT00909402 - Retrieved August 2011 | Bristol-Myers Squibb | Exelixis | Currently recruiting |